Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00432679
Status:
COMPLETED
Last Update Posted:
2022-12-12
First Post:
2007-02-06
Brief Title:
A Study Of BRL49653C For The Treatment Of Type 2 Diabetes Combination Therapy With Sulfonyl Urea -With Placebo Study
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Clinical Evaluation of Rosiglitazone Maleate BRL49653C in Patients With Type 2 Diabetes Mellitus Combination Therapy With Sulfonyl Urea - A Placebo-Controlled Double-Blind Study -
Status:
COMPLETED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed to compare the efficacy and safety of BRL49653C versus placebo with concomitant use of sulfonyl urea SU
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None